<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial systemic therapy in locally advanced or metastatic basal cell carcinoma not amenable to locoregional therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial systemic therapy in locally advanced or metastatic basal cell carcinoma not amenable to locoregional therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial systemic therapy in locally advanced or metastatic basal cell carcinoma not amenable to locoregional therapy</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This treatment approach is for patients with BCC that is metastatic or locoregionally advanced and not amenable to locoregional therapy. The decision to start systemic therapy and the selection of agent(s) depend on availability and access to treatment, disease-related symptoms, and patient performance status and comorbidities. Given the rarity of this disease, clinical trials are encouraged at any time during treatment, where available.</div><div class="graphic_footnotes">BCC: basal cell carcinoma; HHI: hedgehog pathway inhibitors.<br/>* Itraconazole is a reasonable alternative option in resource-limited settings.<br/>¶ For patients without access to HHI who are eligible for immunotherapy, cemiplimab is a reasonable alternative.<br/>Δ Patients who are unable to tolerate the toxicities of continuous dosing of vismodegib may be offered an intermittent dosing schedule. Refer to UpToDate content on systemic treatment of advanced cutaneous basal cell carcinomas.<br/><span class="lozenge">◊</span> Multiple clinical factors influence eligibility for immunotherapy including patient performance status, medical comorbidities, history of autoimmune disease, and use of immunosuppressive therapy or glucocorticoids. Refer to UpToDate content on systemic treatment of metastatic melanoma with molecular alterations.<br/>§ Response rates are limited for these agents, based on available data. Carboplatin plus paclitaxel may result in higher rates of clinical response and is administered intravenously, whereas itraconazole may be better tolerated and is available orally. Clinical trials are encouraged.</div><div id="graphicVersion">Graphic 131715 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
